Ken Drazan, ArsenalBio CEO
On final dash to the clinic, ArsenalBio hauls in $220M for 'modular' cell therapy approach
If ArsenalBio does it right, its first CAR-T candidate — a potential treatment for ovarian cancer — will be in the clinic later this year.
And a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
